BM32: Phase IIb data
Data from 141 evaluable patients with grass pollen allergy in a double-blind, European Phase IIb trial showed that subcutaneous BM32 improved the mean daily combined symptom and medication score, the primary endpoint, by 22% vs. placebo (p=0.085). BM32 also significantly reduced rhinoconjunctivitis symptom score during the peak pollen season in the second treatment year by...
Read the full 255 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$35 USD
